PCAC Vote Results: FDA Panel Backs 6 of 7 Peptides for Compounding

Meeting overview

FDA’s meeting record identifies the seven groups of substances and evaluated uses. It links the presentations, questions and recordings. These materials describe a review process, not an approval of every preparation sold under a peptide’s common name.

Leslie Liang’s July 28 report in The BMJ identifies six favorable recommendations, with emideltide the exception. The final FDA decision is separate. An unfavorable vote does not bind the agency either, and we have not verified a fixed implementation timetable.

Day 1 vote results (July 23)

Pharmaceutical Executive’s July 24 recap reports the following counts. This review has not independently checked an official tally for every free-base and acetate vote. Counts are presented in yes/no order, with abstentions separately; they do not establish a single panel size for every vote.

FDA’s agenda distinguishes free-base and acetate forms. Its introductory slides explain that listing one salt or form does not automatically cover another. The slides also state that eventual listing is not automatically limited to the evaluated use or route unless the entry imposes restrictions. Both details matter when translating a headline into a product-specific claim.

The advisory panel reshuffle

The BMJ reported concerns about committee members’ peptide-business interests. Such relationships are relevant context for evaluating an advisory process, but they are not proof that an individual vote was corrupt or that a scientific conclusion is wrong. We are not inferring an individual member’s motive from the result.

The practical task is to examine the evidence and the reasoning on both sides. Greater access, product quality and stronger clinical evidence are different aims; a favorable recommendation does not establish that all three have already been achieved.

Day-by-day schedule

BPC-157: the ulcerative colitis evaluation

FDA’s BPC-157 briefing evaluated ulcerative colitis and discussed limited human reports alongside preclinical research. It did not establish broad gut healing or tissue regeneration in patients. Human reports should not be erased, but their design, preparation and endpoint determine what conclusions they support.

A recommendation is not a prescription or a validated treatment protocol. Nor should the evaluated condition be assumed to become an automatic restriction on any eventual list entry. See our guides on BPC-157 for gut healing, BPC-157 dosage, and BPC-157 side effects. For the separate regulatory questions, see BPC-157 FDA status in 2026.

KPV: promising preclinical findings, unresolved human questions

The original PepT1/KPV study reported anti-inflammatory findings in cells and mouse colitis models. That supports a research rationale, not proof of clinical benefit for inflammatory bowel disease or wound healing. It also does not establish a universal “clean safety record” or justify ranking KPV as the strongest clinical evidence in this group.

The reported favorable vote does not close those evidence gaps. See our coverage on KPV for gut health, KPV benefits, and KPV dosage.

TB-500: distinguish the fragment from thymosin beta-4

FDA’s TB-500 briefing distinguishes the N-acetylated seven-amino-acid fragment from its 43-amino-acid thymosin beta-4 parent. It identifies naming and preparation ambiguities and a lack of identified human clinical evidence for the evaluated fragment and use. Research on the parent cannot simply be transferred to a product called TB-500.

Patient and athlete accounts may describe experiences worth discussing, but without a clear product identity they cannot resolve those uncertainties. See our guides on TB-500 dosage, BPC-157 vs TB-500, and the BPC-157 + TB-500 blend for evidence context.

MOTS-c: novel mitochondrial peptide, thin clinical data

Lee and colleagues’ original MOTS-c study reported metabolic findings in mice, including effects on obesity and insulin resistance. These are preclinical findings, not a demonstrated obesity or osteoporosis treatment in humans. Observing a naturally occurring peptide in people is also different from testing an administered product.

The advisory outcome does not itself validate a dose, schedule or preparation. See our MOTS-c peptide overview and MOTS-c dosage for the research context.

Day 2: emideltide (DSIP), Semax, Epitalon

Nicole Lou’s July 24 reporting, republished by NAMD, gives the following counts for the free-base and acetate versions. We have not independently verified each official tally. “7–6 against” emideltide is displayed here as six yes and seven no, keeping the column order consistent.

A vote margin does not reveal every member’s reasoning or rank clinical effectiveness. FDA’s Day 2 assessments identify substance-characterization and clinical-evidence limitations for the evaluated preparations. That is narrower than claiming that there has been no human research or that research outside the United States is inherently unreliable.

• DSIP (delta sleep-inducing peptide, emideltide): Distinguish the unfavorable advisory recommendation from a binding agency decision. See our DSIP peptide guide.
• Semax: Study preparation, patient population and endpoint matter when interpreting human reports; the vote does not establish general cognitive enhancement. See Semax peptide and Semax vs Selank.
• Epitalon: The evaluated use was insomnia. A favorable recommendation does not validate longevity claims. See Epitalon benefits.

How to submit a public comment

This meeting’s participation deadlines have passed. For the record and any future opportunity:

1. Go to regulations.gov and open docket FDA-2025-N-6895, the docket for the July 23-24, 2026 PCAC meeting.
2. Past deadlines: FDA specified July 9, 2026 for distribution to committee members and July 22, 2026 as the final written-comment deadline.
3. The notice used the shared meeting docket above; do not assume that each substance requires a different docket.
4. Public submissions can expose identifying details. Do not include identifiable patient information in an ordinary public comment; follow any applicable confidential-submission instructions.
5. For a future hearing or proposed rule, check that new notice’s deadline and participation instructions. Old speaking-registration instructions do not apply to a meeting that has ended.

What to watch after the meeting

Three separate records are useful to follow:

• Official meeting records: Check the actual question, substance form, vote and explanation rather than inferring motives from a margin.
• Agency action: Distinguish a proposal, interim policy and final effective rule. A press report is not the operative document.
• Clinical evidence: Look for studies of the actual preparation and relevant outcomes, including adverse events and longer follow-up—not only evidence of market demand.

Related regulatory actions

The PCAC meeting should not be confused with other regulatory threads:

• Nomination/category changes: FDA’s May 14, 2026 category document records withdrawal-related and route-specific changes, not a uniform April 2025 legalization. See the fourteen-peptide status guide.
• 503B GLP-1 action: FDA’s April 30 announcement described a proposal concerning semaglutide, tirzepatide and liraglutide under a different framework. See FDA 503B GLP-1 exclusion; do not treat that proposal as a July PCAC decision.
• Product-specific enforcement: FDA’s August 24 Peak Performance Peptides letter illustrates that a research-use disclaimer did not override evidence of intended human use for the products cited there. It is not a laboratory test of every peptide supplier. See FDA peptide ban.
• Other substances: The seven-group agenda does not determine the status of every peptide. For example, kisspeptin requires its own form-specific check; the category document includes kisspeptin-10 in Category 2. Absence from this meeting is not proof of absence from every regulatory process.

Does this open a dietary supplement pathway?

The meeting did not create a dietary supplement authorization. FDA’s dietary-ingredient explanation describes separate requirements. A new dietary ingredient notification, where required, is submitted at least 75 days before marketing; it is not drug approval. The law also includes an exception for certain ingredients already present in the food supply in an unaltered chemical form.

Drug-exclusion rules are also fact-specific: FDA describes exclusions involving approved drugs or authorized drug investigations where substantial clinical investigations have begun and become public, subject to prior-marketing exceptions. We are not deciding every peptide’s eligibility from an assumed confidential investigation or from its name alone.

In short, a compounding recommendation, a dietary-ingredient submission and a lawful retail product are not interchangeable. Product form and intended use matter. We cover the distinction in peptide supplements: what is actually legal to buy, and formulation-specific absorption questions in oral peptides.

Bottom line

FDA’s comparison of the statutory provisions distinguishes patient-specific and limited anticipatory 503A compounding from 503B production without patient-specific prescriptions. It also distinguishes qualifying 503A exemptions from 503B current good manufacturing practice requirements. A committee recommendation does not replace these conditions.

The reported six favorable recommendations are an advisory milestone, not a universal finding of safety, efficacy or legal availability. Final-list placement and conditional interim policies must be checked against the actual 503A framework; 503B has separate requirements. Ask which specific preparation and dated authority support an access claim. Neither a research label nor a prescription alone settles every requirement.

Sources

Primary FDA documents and original studies are linked at the relevant claims above. Vote counts are attributed to the reporting actually retrieved, with the official-tally limitation stated beside each table. The earlier background-coverage links below are retained for context; they are not substitutes for operative FDA documents, and older predictions may have been superseded.

• FDA: July 23-24, 2026 Meeting of the PCAC
• NPR: FDA scientists flag concerns with peptides ahead of the July panel
• AJMC: FDA to Convene Expert Panel on Expanding Access to Peptides
• Lengea Law: FDA Puts BPC-157, TB-500, and Five Other Peptides Under the Microscope
• Loti Labs: FDA Peptide Regulations 2026
• Fortune: The FDA peptide vote could create telehealth's next market (July 20, 2026)
• Forbes: FDA's Review of Peptides Signals a Growing Public Health Challenge (July 21, 2026)
• NutraIngredients: FDA peptide panel raises questions about future dietary supplement pathway (July 27, 2026)
• Washington Post: FDA raised conflict-of-interest concerns ahead of the new peptide panel (July 17, 2026)